Infliximab Delays but Does Not Avoid the Need for Surgery in Treatment-Resistant Pediatric Crohn’ Disease
- First Online:
- 119 Downloads
The aim of this study was to review the impact of infliximab therapy on children with treatment-resistant Crohn’s disease. Treatment resistance was defined as clinically active disease despite > 4 months of immunosuppressive therapy. The outcome variables were time to first remission, duration of remission and the need for surgery. 24 children received 90 infusions of infliximab (16 boys; median 10.3y, range 1.0–14.4y); all had three infusions as an induction course. 17 (70.8%) achieved clinical remission, with 14/17 (82.3%) relapsing within 4 months of the third infusion. 6/7 in the non-responding group and 8/17 of the responders required surgery with an insignificant difference in the median time to surgery (p = 0.49). Four remain dependent on regular infliximab. Infliximab is well-tolerated and highly effective in achieving clinical remission in children with refractory Crohn’s disease but may only delay and not avoid the need for surgery. Failure to achieve clinical remission by the 3rd infusion significantly increases the risk of surgery.
Key wordsinfliximab child Crohn’s disease inflammatory bowel disease treatment resistance surgery
Unable to display preview. Download preview PDF.
- 3.Hyams JS: Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr Gastroenterol Nutr 33 (Suppl 1):S36–S39, 2001Google Scholar
- 5.Kugathasan S: Prolonged duration of response to infliximab in early pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 33 (Suppl 1):S40–S43, 2001Google Scholar
- 6.Harvey RF, Bradshaw MJ: Measuring Crohn’s disease activity. Lancet 1(8178):1134–1135, 1980Google Scholar
- 7.Harvey RF, Bradshaw JM: A simple index of Crohn’s-disease activity. Lancet 1(8167):514, 1980Google Scholar
- 10.Gasche C, Scholmerich J, Brynskov J, et al.: A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis6(1):8–15, 2000Google Scholar
- 12.Bousvaros, A: Oral tacrolimus treatment of fulminant colitis in children: long term follow-up. J Pediatr Gastroenterol Nutr 27(4):463, 1998 (abstract)Google Scholar
- 15.Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549, 2002Google Scholar
- 18.Lionetti P, Bronzini F, Salvestrini C, et al.: Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther 18(4):425–431, 2003Google Scholar